Marek Lommatzsch

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

J. Mark FitzGerald, Eugene R. Bleecker, Parameswaran Nair et al. · The Lancet · 2016 · 1.4K citations

Pharmacy, Immunology, Pharmacology +17

The impact of age, weight and gender on BDNF levels in human platelets and plasma

Marek Lommatzsch, Doerte Zingler, Katharina Schuhbaeck et al. · Neurobiology of Aging · 2004 · 838 citations

Medicine, Geriatric Medicine, Hematology +6

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

William W. Busse, Eugene R. Bleecker, J Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 311 citations

Pharmacy, Pharmacology, Pharmacotherapy +6

Abundant Production of Brain-Derived Neurotrophic Factor by Adult Visceral Epithelia

Marek Lommatzsch, Armin Braun, Anne G. Mannsfeldt et al. · American Journal Of Pathology · 1999 · 275 citations · Full text

Medicine, Neurobiology, Neuroscience +10

Neurotrophins Are Increased in Bronchoalveolar Lavage Fluid after Segmental Allergen Provocation

JOHANN CHRISTIAN VIRCHOW, Peter Julius, Marek Lommatzsch et al. · American Journal of Respiratory and Critical Care Medicine · 1998 · 259 citations

Life Sciences, Immunology, Physiology +11